Median OS was 20.9 months in the motesanib plus C/P arm and 14.5 months in the placebo plus C/P arm ( P = 0.0223 ) ; median PFS was 7.0 and 5.3 months , respectively , ( P = 0.0004 ) ; and ORR was 62 % and 27 % , respectively , ( P < 0.0001 ) .